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Immunotherapy for glioblastoma (GBM) is the subject
of numerous clinical trials, given the potential for the
adaptive immune response to combat this diffusely infil-
trating tumor. However, rational application of immu-
notherapy to these tumors is challenging because of the
peculiar immune privilege of the brain and the molecu-
lar heterogeneity of glioma antigens. Little is known
about patient-to-patient variability in the potential to
generate anti-glioma immune responses of their sys-
temic and local T cell populations.
We conducted a foundational study of the population-
wide characteristics of both the peripheral blood and
local, tissue-infiltrating T lymphocytes (TILs) of glioma
patients using TCRseq. Through reverse transcription
and pan-repertoire amplification of the TCR-alpha and
-beta chains we generated TCRseq libraries from
matched surgical tissue and peripheral blood cells. Using
peripheral blood samples from primary GBM, low-grade
glioma, and non-tumor patients (N=14), we define new
immunophenotypes using statistical metrics based on
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information theory – specifically, the clonality associated
with antigen-binding function in the TCRs of TIL, and
the antigen-binding associated divergence of the TIL
population from the blood. We found that diversification
of this repertoire was characteristic of high-grade tumors,
and correlated strongly with the activation of specific
immune and inflammatory pathways. Furthermore, we
found strong correlation between usage of a subset of
TCR sequences in patients’ peripheral blood and the
divergence of their TIL population from the peripheral
repertoire. We anticipate that these immunophenotypes
will be key to monitoring and predicting response to
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anti-glioma vaccines and immunotherapy, and under-
standing the immunological mechanisms determining
their efficacy.
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